Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Immunoenzyme Techniques 5Flow Cytometry 4Standard of Care 3Psychiatric Rehabilitation 3Surveys and Questionnaires 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Microarray Analysis 2Interviews as Topic 2Immunologic Techniques 2Gene Expression Profiling 2Amplified Fragment Length Polymorphism Analysis 2plerixafor 1Watchful Waiting 1Urination 1Platelet Aggregation 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Lenalidomide 1Influenza Vaccines 1In Situ Hybridization, Fluorescence 1Immunosuppression Therapy 1Glycopeptides 1Focus Groups 1Fentanyl 1Enzyme-Linked Immunosorbent Assay 1Enteral Nutrition 1Electrophoresis, Polyacrylamide Gel 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms, Plasma Cell × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡